In addition, the study will evaluate the effect of sequential
dosing with
tenofovir for 12 weeks, following monotherapy SB 9200, for possible synergistic effects on the reduction of HBV DNA and HBsAg.”
This Phase 2a study has an adaptive trial design that will enroll 80 chronically-infected HBV patients between 18 and 70 years of age who will be assigned to one of four dosing cohorts, 25 mg, 50 mg, 100 mg or 200 mg of SB 9200, or placebo, once daily for 12 weeks.